North America Autoimmune Disease Diagnostics Market Report by Product, Type, Indication, End User, Countries and Companies Analysis 2026-2034

North America Autoimmune Disease Diagnostics Market Size and Forecast 2026-2034

North America Autoimmune Disease Diagnostics Market will grow from US$ 2.09 Billion in 2025 to US$ 3.73 Billion in 2034, at a Compound Annual Growth Rate (CAGR) of 6.66% from 2026-2034. The market growth is driven by rising prevalence of autoimmune disorders, increasing demand for early and accurate diagnosis, and advancements in biomarker-based testing and molecular diagnostics.

North America Autoimmune Disease Diagnostics Market Outlooks

Autoimmune disease diagnostics refers to the set of laboratory and clinical tests used to detect, identify, and monitor autoimmune disorders, where the immune system mistakenly attacks the body's own tissues. These diagnostics include blood tests such as antinuclear antibody (ANA) testing, rheumatoid factor (RF), C-reactive protein (CRP), and advanced molecular and genetic assays that help identify specific autoimmune conditions like rheumatoid arthritis, lupus, multiple sclerosis, and type 1 diabetes.

In North America, autoimmune disease diagnostics are highly popular due to the rising prevalence of chronic autoimmune conditions and strong healthcare awareness. The region has a well-developed healthcare infrastructure, enabling widespread adoption of advanced diagnostic technologies in hospitals, diagnostic laboratories, and research centers. These tests are widely used for early disease detection, treatment monitoring, and personalized therapy planning. Increasing demand for precision medicine and biomarker-based testing is further driving adoption.

Additionally, continuous innovation in immunoassays, next-generation sequencing, and point-of-care testing is improving accuracy and turnaround time. As a result, autoimmune diagnostics play a crucial role in improving patient outcomes and supporting effective disease management across the United States and Canada.

Autoimmune Disease Diagnostics Product Launches in North America

Year Company / Product Launch / Regulatory Event Indication / Focus

Feb-25 AliveDx - MosaiQ AiPlex(R) CD FDA 510(k) submission for multiplex celiac autoimmune assay Celiac disease (autoimmune)

Apr-25 AliveDx - MosaiQ AiPlex(R) CTDplus FDA 510(k) submission for connective tissue disease microarray SLE, RA, Sjogren's, systemic autoimmune diseases

Sep-25 AliveDx - MosaiQ AiPlex(R) VAS FDA 510(k) submission for vasculitis assay ANCA-associated vasculitis, autoimmune kidney disease

Aug-25 AliveDx - MosaiQ Platform FDA Class II exempt registration (U.S. launch enablement) Multiplex autoimmune + allergy diagnostics

Aug-25 AliveDx - MosaiQ Instrument Expansion U.S. FDA registration enabling clinical lab use Broad autoimmune diagnostics platform

Jan-25 Werfen - Aptiva APS Reagents FDA 510(k) clearance for APS diagnostic reagents Antiphospholipid syndrome

2024 Major U.S. lab networks (Abbott/Siemens/others panels expansion) Expansion of autoimmune immunoassay panels Broad autoimmune screening

2025 AliveDx MosaiQ CTDplus ecosystem Commercial expansion after CE/FDA submissions Systemic autoimmune diseases

2025-2026 MosaiQ Vasculitis (VAS) assay U.S. FDA review pipeline + EU availability Vasculitis / Goodpasture's disease

Growth Drivers of the North America Autoimmune Disease Diagnostics Market

Rising Prevalence of Autoimmune Disorders

The increasing prevalence of autoimmune diseases is a major growth driver for the North America autoimmune disease diagnostics market. Conditions such as rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, and inflammatory bowel disease are becoming more common due to genetic, environmental, and lifestyle-related factors. Early detection is critical for managing these chronic conditions effectively, which is increasing the demand for advanced diagnostic testing. Healthcare providers in the United States and Canada are focusing on early and accurate diagnosis to prevent long-term complications and improve patient quality of life. This has led to higher adoption of laboratory-based immunoassays, molecular diagnostics, and biomarker testing. Additionally, awareness among patients and physicians regarding autoimmune symptoms has improved significantly, resulting in higher screening rates. As the disease burden continues to rise across all age groups, the demand for reliable and advanced diagnostic solutions is expected to grow steadily across North America. Over 15 million people, or 4.6% of the US population, have been diagnosed with at least one autoimmune disease between 2011 and 2022, with 34% of these diagnosed with two or more autoimmune diseases.

Advancements in Diagnostic Technologies

Technological advancements are significantly driving the growth of the autoimmune disease diagnostics market in North America. Innovations such as next-generation sequencing (NGS), multiplex immunoassays, flow cytometry, and high-sensitivity biomarker detection are improving diagnostic accuracy and efficiency. These technologies allow early identification of autoimmune conditions even before severe symptoms appear, enabling timely treatment interventions. Automation in laboratories has also reduced testing time and improved throughput, making diagnostics more accessible and cost-effective. Artificial intelligence and machine learning are increasingly being integrated into diagnostic platforms to enhance data interpretation and disease prediction. Additionally, the development of point-of-care testing devices is expanding access to diagnostics outside traditional laboratory settings. These technological improvements are not only enhancing clinical outcomes but also supporting the shift toward precision medicine. As innovation continues, diagnostic capabilities are expected to become more advanced, personalized, and widely available across North America. Feb 2025, YESINTEK (ustekinumab-kfce), indicated for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, is available in the US.

Strong Healthcare Infrastructure and High Awareness

North America benefits from a highly developed healthcare infrastructure and strong awareness regarding autoimmune diseases, which supports market growth. The United States and Canada have advanced hospital networks, well-equipped diagnostic laboratories, and widespread access to specialized healthcare services. This enables rapid adoption of new diagnostic technologies and standardized testing protocols. Additionally, high awareness among patients and healthcare professionals leads to early screening and diagnosis, which is essential for managing autoimmune conditions effectively. Government initiatives, insurance coverage, and reimbursement policies further encourage patients to undergo diagnostic testing. Research institutions and pharmaceutical companies in the region are also actively involved in studying autoimmune diseases, driving demand for advanced diagnostic tools. Continuous investment in healthcare modernization ensures the availability of cutting-edge laboratory technologies. Together, these factors create a strong ecosystem that supports consistent growth of the autoimmune disease diagnostics market across North America. April 2025, The U.S. approved a 5.06% average hike in reimbursement rates for 2026 Medicare Advantage plans operated by private insurers, well above the January proposal. This rate impacts monthly premiums, plan benefits, and insurer profits for insurers administering healthcare to individuals 65 and older or disabled.

Challenges of the North America Autoimmune Disease Diagnostics Market

High Cost of Advanced Diagnostic Tests

One of the major challenges in the North America autoimmune disease diagnostics market is the high cost of advanced testing methods. Technologies such as next-generation sequencing, multiplex immunoassays, and biomarker-based panels are expensive, making them less accessible for some patients. Even though insurance coverage is relatively strong in the region, out-of-pocket expenses can still be significant, especially for repeated or long-term diagnostic monitoring. Smaller healthcare facilities and laboratories may also struggle with the high cost of installing and maintaining advanced diagnostic equipment. This cost barrier can delay early diagnosis, particularly for patients without comprehensive insurance coverage. Additionally, pricing variability between different providers creates inconsistencies in access to diagnostic services. While technological advancements are improving accuracy and efficiency, affordability remains a concern. Addressing this challenge requires better reimbursement frameworks, cost optimization strategies, and wider adoption of scalable diagnostic platforms to ensure broader accessibility across all patient groups.

Complexity and Difficulty in Early Diagnosis

Autoimmune diseases are often difficult to diagnose in their early stages due to overlapping symptoms with other conditions, making diagnostic accuracy a significant challenge. Many autoimmune disorders develop gradually and present nonspecific symptoms such as fatigue, joint pain, and inflammation, which can be mistaken for other illnesses. This complexity often leads to delayed or misdiagnosis, affecting treatment outcomes. Even with advanced diagnostic tools, no single test can definitively confirm many autoimmune conditions, requiring multiple tests and clinical evaluations. This increases diagnostic time and healthcare costs. Additionally, variability in biomarkers among patients further complicates interpretation of results. Healthcare professionals must rely on a combination of laboratory tests, imaging, and patient history, which adds to the complexity. Despite technological progress, improving early and accurate detection remains a key challenge. Enhanced biomarker discovery and integration of AI-driven diagnostic systems are needed to overcome these limitations in North America.

North America Autoimmune Disease Therapeutic & Monitoring Market

The North American autoimmune disease therapeutic and monitoring market is expanding steadily due to the rising number of patients diagnosed with chronic immune-mediated conditions and the growing emphasis on long-term disease management. Treatment approaches commonly include biologic therapies, targeted immunosuppressants, and combination drug regimens, which require continuous monitoring to ensure safety and effectiveness. Integrated care models are becoming increasingly important, combining diagnostics, treatment, and real-time patient monitoring into a unified healthcare approach. This integration improves treatment outcomes and reduces disease complications. Additionally, digital health technologies, such as remote patient monitoring systems, wearable devices, and mobile health applications, are transforming disease management by enabling continuous tracking of symptoms and treatment response. Healthcare providers are increasingly adopting data-driven decision-making tools to personalize therapy plans. As chronic autoimmune conditions continue to rise, demand for advanced therapeutic solutions and efficient monitoring systems is expected to strengthen across North America.

North America Systemic Autoimmune Disease Diagnostics Market

Systemic autoimmune disease diagnostics in North America are expanding due to the complex nature of disorders such as systemic lupus erythematosus, multiple sclerosis, and systemic sclerosis, which affect multiple organs. These conditions require comprehensive diagnostic approaches involving blood analysis, autoantibody profiling, imaging techniques, and genetic testing. Increasing awareness among healthcare professionals and patients has led to earlier screening and improved disease detection rates. Government funding and academic research initiatives are playing a key role in advancing diagnostic methodologies and improving clinical understanding of systemic autoimmune diseases. Enhanced laboratory infrastructure and adoption of high-precision diagnostic tools are enabling faster and more accurate patient evaluation. Early diagnosis is critical for preventing irreversible organ damage and improving long-term outcomes. As research continues to uncover new biomarkers, diagnostic accuracy and efficiency are expected to improve further, strengthening systemic autoimmune disease diagnostics across North America.

North America Localized Autoimmune Disease Diagnostics Market

The localized autoimmune disease diagnostics market in North America is growing steadily, driven by increasing cases of conditions such as psoriasis, Hashimoto's thyroiditis, and vitiligo, which affect specific organs or tissues. Diagnosis typically involves targeted tests such as hormone level assessments, tissue biopsies, skin evaluations, and clinical examinations. Strong dermatology and endocrinology healthcare networks in the region support accurate and timely diagnosis of these localized disorders. Rising patient awareness and demand for specialized care services are also contributing to market expansion. The availability of specialty clinics and advanced diagnostic laboratories ensures better disease identification and management. Additionally, pharmaceutical companies are increasingly collaborating with diagnostic providers to develop companion diagnostic tools that align with targeted therapies. These partnerships enhance treatment precision and improve patient outcomes. As precision medicine advances, localized autoimmune disease diagnostics are expected to play an increasingly important role in personalized healthcare across North America.

North America Diabetes Autoimmune Disease Diagnostics Market

The autoimmune diabetes diagnostics market in North America is expanding due to the rising prevalence of Type 1 diabetes, particularly among children and young adults. Early detection relies on autoantibody testing, blood glucose monitoring, and insulin production assessments to confirm disease onset and progression. Timely diagnosis is essential for initiating insulin therapy and preventing severe complications such as ketoacidosis and long-term organ damage. Public health initiatives, school-based screening programs, and pediatric awareness campaigns are significantly improving early detection rates, especially in the United States. Advanced diagnostic tools are enabling more accurate identification of at-risk individuals before clinical symptoms fully develop. Healthcare providers are also focusing on continuous glucose monitoring systems and predictive diagnostic approaches to improve disease management. With increasing awareness and technological advancements, the demand for early and precise autoimmune diabetes diagnostics is expected to grow steadily across North America.

North America Autoimmune Rheumatic Disease Diagnostics Market

The autoimmune rheumatic disease diagnostics market in North America is witnessing strong growth due to the high prevalence of conditions such as rheumatoid arthritis, scleroderma, and ankylosing spondylitis. Diagnostic procedures include rheumatoid factor (RF) testing, anti-CCP antibody tests, inflammatory marker analysis, and advanced imaging techniques like MRI and ultrasound. Well-established rheumatology clinics and specialized healthcare centers across the region support early and accurate disease identification. Increasing patient awareness and active participation from advocacy groups are further driving demand for timely diagnosis and treatment. Clinical research activities and ongoing drug development trials are also contributing to the need for precise diagnostic tools. Early diagnosis is critical for preventing joint damage and improving long-term patient mobility and quality of life. As diagnostic technologies advance, accuracy and speed of detection are expected to improve significantly across North America.

North America Autoimmune Disease Diagnostics Hospitals Market

Hospitals play a central role in autoimmune disease diagnostics across North America due to their advanced infrastructure and integrated healthcare systems. They provide comprehensive diagnostic services, including laboratory testing, imaging, and specialized autoimmune panels under one facility. Many hospitals are affiliated with research institutions, enabling access to clinical trials and experimental diagnostic technologies. This enhances early detection and supports innovation in autoimmune disease management. Chronic autoimmune conditions require continuous monitoring, making hospitals essential for long-term patient care and multidisciplinary treatment coordination. Skilled medical professionals and advanced laboratory systems improve diagnostic accuracy and turnaround times. Additionally, hospitals often collaborate with pharmaceutical and diagnostic companies to implement new testing methods. As autoimmune disease prevalence rises, hospital-based diagnostics are becoming increasingly important for delivering efficient, accurate, and coordinated care across North America.

United States Autoimmune Disease Diagnostics Market

The United States dominates the North American autoimmune disease diagnostics market due to its advanced healthcare system, high disease burden, and strong research ecosystem. Studies indicate that autoimmune disorders affect a significant portion of the population, with conditions such as type 1 diabetes showing increasing incidence. The country benefits from substantial investments in diagnostic research and development, supported by both public and private sectors. Major diagnostic companies such as Quest Diagnostics and LabCorp play a key role in expanding testing accessibility and innovation. Strong reimbursement policies and widespread insurance coverage further support market growth. Additionally, the expansion of telehealth services and preventive care programs has improved early detection and disease management. Venture capital investments, such as funding in early-stage diagnostic startups, are also accelerating innovation. These factors collectively strengthen the United States' leadership position in autoimmune disease diagnostics across North America. In February 2023, CerraCap Ventures, a Venture Capital fund, made a strategic investment in Predicta Med, a prominent early-stage startup specializing in assisting medical clinics and institutions in the early detection and management of immune-related diseases

Canada Autoimmune Disease Diagnostics Market

The autoimmune disease diagnostics market in Canada is growing steadily due to universal healthcare coverage, which ensures broad access to essential diagnostic services. The country has a well-developed laboratory network and a strong collaborative research environment that supports innovation in disease detection. Rising incidence of autoimmune disorders and increasing awareness among both patients and healthcare professionals are driving demand for early and accurate diagnostics. Government support for healthcare innovation and patient education initiatives further encourages adoption of advanced diagnostic technologies. Recent regulatory approvals for novel blood-based diagnostic tests highlight Canada's progress in improving disease detection capabilities. Hospitals and diagnostic laboratories are increasingly integrating advanced immunoassays and molecular testing platforms. As healthcare infrastructure continues to evolve, Canada is expected to see continued growth in autoimmune diagnostics, supported by innovation, accessibility, and strong public health systems. Nov 2025 - Augurex Life Sciences Corp. announced the upcoming launch of the 14-3-3eta test, approved as JOINTstat(R) in Canada and the UK, through Sonic Reference Laboratory, a division of Sonic Healthcare USA. Beginning December 15, 2025, the test will be available to healthcare providers across the United States as part of Sonic's diagnostic portfolio. The 14-3-3eta test improves early detection and management of rheumatoid arthritis (RA), providing clinicians with a powerful tool to enhance care and optimize outcomes.

Mexico Autoimmune Disease Diagnostics Market

The autoimmune disease diagnostics market in Mexico is experiencing gradual growth driven by increasing awareness of chronic immune disorders and improving access to healthcare services. Urban hospitals and diagnostic laboratories are adopting more advanced technologies for autoimmune disease detection, while rural regions still face challenges related to limited infrastructure and access to specialized care. Government healthcare reforms aimed at expanding universal coverage are helping improve diagnostic accessibility across the country. International collaborations and partnerships with global healthcare organizations are also strengthening diagnostic capabilities and knowledge transfer. Rising prevalence of chronic diseases is encouraging investment in better diagnostic facilities and laboratory modernization. Public health initiatives focused on early detection and disease management are expected to further support market expansion. Although disparities remain, ongoing improvements in healthcare infrastructure are likely to enhance autoimmune disease diagnostics across Mexico in the coming years.

Market Segments

Product

• Therapeutic & Monitoring Equipment
• Diagnostics Equipment
• Drugs

Type

• Systemic
• Localized

Indication

• Rheumatic Disease
• Diabetes
• Multiple Sclerosis
• Inflammatory Bowel Disease
• Others

End Users

• Hospitals
• Diagnostics Centers
• Others

Countries

• United States
• Canada
• Mexico
• Rest of North America

Companies have been covered from 5 viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Bio-Rad Laboratories
• Abbott Laboratories
• Roche Diagnostics
• Quest Diagnostics Incorporated
• Thermo Fisher Scientific Inc.
• BioMerieux SA
• Myriad Genetics, Inc.
• Siemens Healthineers